Neurofibromatosis Type 1 (NF1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
- Published Date : October 18, 2024
- Updated On : April 22, 2025
- Pages : 151
Neurofibromatosis Type 1 (NF1) Market Outlook
Thelansis’s “Neurofibromatosis Type 1 (NF1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neurofibromatosis Type 1 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Neurofibromatosis Type 1 (NF1) Overview
Neurofibromatosis type 1 (NF1) is a neurocutaneous genetic disorder characterized by its diverse clinical manifestations, including café-au-lait spots, Lisch nodules in the iris, freckling in the axillary and inguinal regions, and multiple neurofibromas. NF1 condition exhibits significant variability in clinical features, even among individuals within the same family. Almost all patients display multiple café-au-lait macules; some present at birth, and most emerge within the first year of life. Intertriginous freckling typically begins around the age of 5. In adults, cutaneous and subcutaneous neurofibromas develop and continue to increase in number and size with age. It’s important to note that these cutaneous neurofibromas do not turn malignant. However, plexiform neurofibromas, which grow along nerves and their branches, may cause disfigurement, pain, and functional impairments. They are usually present at birth and may develop into malignant tumors later in life.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Neurofibromatosis Type 1 (NF1) Market Outlook
Thelansis’s “Neurofibromatosis Type 1 (NF1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neurofibromatosis Type 1 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Neurofibromatosis Type 1 (NF1) Overview
Neurofibromatosis type 1 (NF1) is a neurocutaneous genetic disorder characterized by its diverse clinical manifestations, including café-au-lait spots, Lisch nodules in the iris, freckling in the axillary and inguinal regions, and multiple neurofibromas. NF1 condition exhibits significant variability in clinical features, even among individuals within the same family. Almost all patients display multiple café-au-lait macules; some present at birth, and most emerge within the first year of life. Intertriginous freckling typically begins around the age of 5. In adults, cutaneous and subcutaneous neurofibromas develop and continue to increase in number and size with age. It’s important to note that these cutaneous neurofibromas do not turn malignant. However, plexiform neurofibromas, which grow along nerves and their branches, may cause disfigurement, pain, and functional impairments. They are usually present at birth and may develop into malignant tumors later in life.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
